Agree. But this is not a specific issue with omics. Comes down to a lack of serious consideration of expt. designs that can enable answering well defined questions. Vague problem definitions/formulations, arbitrary designs, scaling modalities just cuz u can. Huge waste.

🔥Does academia stifle creativity? This new perspective argues that academia is currently structured to select against creativity, intellectual risk-taking and bold ideas. Young scientists – who may be best positioned for new ideas – are particularly incentivized to play it safe.

Accurately quantifying over 700K precursors in a single 9-plexDIA set of 20ng proteomes is a new milestone. JMod achieves high quantitative accuracy over a 32-fold dynamic range of proteome spiked-in ratios across single-cell and bulk sample sizes. 1/ doi.org/10.1101/2025.05.22.6…

A new pharmacological strategy -- based on engineering protein surfaces -- just achieved major success against pancreatic cancer. It points toward a much broader class of cancer therapies. Yesterday, the FDA approved daraxonrasib (Rasonque), a drug that targets the RAS proteins driving most pancreatic cancers. What makes it especially fascinating is how it works. Rather than simply finding a conventional pocket on RAS, daraxonrasib binds the chaperone protein cyclophilin A and uses it to create a new protein surface. This drug–cyclophilin complex then engages active RAS, forming a three-part complex that blocks RAS interactions with downstream effectors. Remarkably, the complex can also stimulate GTP hydrolysis, further suppressing RAS signaling. This is chemical biology at its most powerful: a small molecule is not merely inhibiting a protein: It is engineering a new protein–protein interaction inside the cell to pharmacologically control a previously “undruggable” protein. The clinical impact is already impressive: in a randomized phase III trial, median survival in metastatic pancreatic cancer increased from 6.7 to 13.2 months compared with standard chemotherapy. 🔷 Perhaps the most exciting aspect is what comes next. If we can pharmacologically engineer new protein surfaces and interactions, rather than being restricted to naturally occurring binding pockets, the universe of druggable proteins—and potentially the range of cancers we can treat—could expand dramatically. A beautiful example of how understanding and engineering proteins can open entirely new therapeutic possibilities.